Request for Information on CDC Procurement of Clinical Specimens

The Centers for Disease Control and Prevention (CDC) Office of Laboratory Systems and Response is issuing a Sources‑Sought Request for Information (RFI) to collect data on the acquisition of de‑identified human clinical specimens and synthetic specimen matrices for use in the development and validation of high‑complexity diagnostic tests. The effort supports the National Biodefense Strategy by building specimen‑procurement capabilities that enable rapid medical‑countermeasure development. Respondents—clinical laboratories, biorepositories, research organizations, diagnostic companies, and other public‑health partners—are asked to provide a brief (≤ 1.5‑page) response consisting of a cover page (entity ID, contact information, NAICS classification, SAM registration, small/large‑business status, and any Federal Supply Schedule or contract references) and an “Approach” section describing end‑to‑end procurement solutions, compliance with 45 CFR 46 (or exemption documentation), capability and capacity (including tables of specimen types, volumes, lead times, and delivery schedules), inclusion/exclusion criteria, available characterization (e.g., HIV, influenza testing), material‑transfer restrictions, and availability of uncommon specimens (e.g., pleural fluid, conjunctival swabs). Respondents must also outline cost factors and rough order‑of‑magnitude pricing, and may suggest preferred contracting mechanisms (IDIQ, BPA, OTA). The RFI is for market research only; responses are non‑binding and will not result in an award. Submissions are to be sent electronically by 5:00 PM ET on the date to be announced, with the subject line “Procurement of Deidentified Specimens for Diagnostic Test Development and Validation: [Company Name]”.

Notice ID

e298f620d9ef4101b9cbf26699e5a17f

Solicitation Number

412026

NAICS Code

N/A

Classification Code

N/A